Report Code: LS12191 | Available Format: PDF
- Home
- Life Sciences
- Benign Prostatic Hyperplasia Treatment Market
Benign Prostatic Hyperplasia Treatment Market Research Report: By Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare Settings, Hospitals & Clinics) – Global Industry Analysis and Demand Forecast to 2030
- Report Code: LS12191
- Available Format: PDF
- Report Description
- Table of Contents
- Market Segmentation
- Request Free Sample Pages
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Type
1.5.2 Market Segmentation by End User
1.5.3 Market Segmentation by Region
1.5.4 Market Segment Analysis of Countries
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Designation
2.2.4 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Definition of Market Segments
6.1 By Type
6.1.1 Drug Treatment
6.1.1.1 Alpha blockers
6.1.1.1.1 Alfuzosin
6.1.1.1.2 Doxazosin
6.1.1.1.3 Tamsulosin
6.1.1.1.4 Silodosin
6.1.1.2 5-Alpha reductase inhibitors
6.1.1.2.1 Finasteride
6.1.1.2.2 Dutasteride
6.1.1.3 Others
6.1.2 Surgical Treatment
6.1.2.1 TURP
6.1.2.2 TUMT
6.1.2.3 TUNA
6.1.2.4 Laser therapy
6.1.2.5 Prostatic stenting
6.1.2.6 UroLift therapy
6.1.2.7 Rezûm therapy
6.1.2.8 Other surgeries
6.2 By End User
6.2.1 Home Healthcare Settings
6.2.2 Hospitals & Clinics
Chapter 7. Industry Outlook
7.1 Market Dynamics
7.1.1 Trends
7.1.2 Drivers
7.1.3 Impact Analysis of Drivers on Market Forecast
7.1.4 Restraints
7.1.5 Impact Analysis of Restraints on Market Forecast
7.2 Impact of COVID-19 on BPH Treatment Market
7.3 Porter’s Five Forces Analysis
7.3.1 Bargaining Power of Buyers
7.3.2 Bargaining Power of Suppliers
7.3.3 Intensity of Rivalry
7.3.4 Threat of New Entrants
7.3.5 Threat of Substitutes
Chapter 8. Policy and Regulatory Landscape
8.1 North America
8.2 Europe
8.3 APAC
8.4 LATAM
8.5 MEA
Chapter 9. Global Market Size and Forecast
9.1 Overview
9.2 Market Revenue, by Type (2015–2030)
9.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
9.2.1.1 Alpha blockers market revenue, by type (2015–2030)
9.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
9.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
9.3 Market Revenue, by End User (2015–2030)
9.4 Market Revenue, by Region (2015–2030)
Chapter 10. North America Market Size and Forecast
10.1 Overview
10.2 Market Revenue, by Type (2015–2030)
10.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
10.2.1.1 Alpha blockers market revenue, by type (2015–2030)
10.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
10.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
10.3 Market Revenue, by End User (2015–2030)
10.4 Market Revenue, by Country (2015–2030)
Chapter 11. Europe Market Size and Forecast
11.1 Overview
11.2 Market Revenue, by Type (2015–2030)
11.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
11.2.1.1 Alpha blockers market revenue, by type (2015–2030)
11.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
11.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
11.3 Market Revenue, by End User (2015–2030)
11.4 Market Revenue, by Country (2015–2030)
Chapter 12. APAC Market Size and Forecast
12.1 Overview
12.2 Market Revenue, by Type (2015–2030)
12.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
12.2.1.1 Alpha blockers market revenue, by type (2015–2030)
12.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
12.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
12.3 Market Revenue, by End User (2015–2030)
12.4 Market Revenue, by Country (2015–2030)
Chapter 13. LATAM Market Size and Forecast
13.1 Overview
13.2 Market Revenue, by Type (2015–2030)
13.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
13.2.1.1 Alpha blockers market revenue, by type (2015–2030)
13.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
13.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
13.3 Market Revenue, by End User (2015–2030)
13.4 Market Revenue, by Country (2015–2030)
Chapter 14. MEA Market Size and Forecast
14.1 Overview
14.2 Market Revenue, by Type (2015–2030)
14.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
14.2.1.1 Alpha blockers market revenue, by type (2015–2030)
14.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
14.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
14.3 Market Revenue, by End User (2015–2030)
14.4 Market Revenue, by Country (2015–2030)
Chapter 15. U.S. Market Size and Forecast
15.1 Overview
15.2 Market Revenue, by Type (2015–2030)
15.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
15.2.1.1 Alpha blockers market revenue, by type (2015–2030)
15.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
15.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
15.3 Market Revenue, by End User (2015–2030)
Chapter 16. Canada Market Size and Forecast
16.1 Overview
16.2 Market Revenue, by Type (2015–2030)
16.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
16.2.1.1 Alpha blockers market revenue, by type (2015–2030)
16.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
16.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
16.3 Market Revenue, by End User (2015–2030)
Chapter 17. Germany Market Size and Forecast
17.1 Overview
17.2 Market Revenue, by Type (2015–2030)
17.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
17.2.1.1 Alpha blockers market revenue, by type (2015–2030)
17.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
17.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
17.3 Market Revenue, by End User (2015–2030)
Chapter 18. France Market Size and Forecast
18.1 Overview
18.2 Market Revenue, by Type (2015–2030)
18.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
18.2.1.1 Alpha blockers market revenue, by type (2015–2030)
18.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
18.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
18.3 Market Revenue, by End User (2015–2030)
Chapter 19. U.K. Market Size and Forecast
19.1 Overview
19.2 Market Revenue, by Type (2015–2030)
19.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
19.2.1.1 Alpha blockers market revenue, by type (2015–2030)
19.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
19.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
19.3 Market Revenue, by End User (2015–2030)
Chapter 20. Italy Market Size and Forecast
20.1 Overview
20.2 Market Revenue, by Type (2015–2030)
20.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
20.2.1.1 Alpha blockers market revenue, by type (2015–2030)
20.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
20.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
20.3 Market Revenue, by End User (2015–2030)
Chapter 21. Spain Market Size and Forecast
21.1 Overview
21.2 Market Revenue, by Type (2015–2030)
21.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
21.2.1.1 Alpha blockers market revenue, by type (2015–2030)
21.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
21.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
21.3 Market Revenue, by End User (2015–2030)
Chapter 22. China Market Size and Forecast
22.1 Overview
22.2 Market Revenue, by Type (2015–2030)
22.2.1 Drug Treatment Market Revenue, by Type (2215–2230)
22.2.1.1 Alpha blockers market revenue, by type (2015–2030)
22.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
22.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
22.3 Market Revenue, by End User (2015–2030)
Chapter 23. Japan Market Size and Forecast
23.1 Overview
23.2 Market Revenue, by Type (2015–2030)
23.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
23.2.1.1 Alpha blockers market revenue, by type (2015–2030)
23.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
23.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
23.3 Market Revenue, by End User (2015–2030)
Chapter 24. India Market Size and Forecast
24.1 Overview
24.2 Market Revenue, by Type (2015–2030)
24.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
24.2.1.1 Alpha blockers market revenue, by type (2015–2030)
24.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
24.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
24.3 Market Revenue, by End User (2015–2030)
Chapter 25. Australia Market Size and Forecast
25.1 Overview
25.2 Market Revenue, by Type (2015–2030)
25.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
25.2.1.1 Alpha blockers market revenue, by type (2015–2030)
25.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
25.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
25.3 Market Revenue, by End User (2015–2030)
Chapter 26. South Korea Market Size and Forecast
26.1 Overview
26.2 Market Revenue, by Type (2015–2030)
26.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
26.2.1.1 Alpha blockers market revenue, by type (2015–2030)
26.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
26.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
26.3 Market Revenue, by End User (2015–2030)
Chapter 27. Brazil Market Size and Forecast
27.1 Overview
27.2 Market Revenue, by Type (2015–2030)
27.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
27.2.1.1 Alpha blockers market revenue, by type (2015–2030)
27.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
27.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
27.3 Market Revenue, by End User (2015–2030)
Chapter 28. Mexico Market Size and Forecast
28.1 Overview
28.2 Market Revenue, by Type (2015–2030)
28.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
28.2.1.1 Alpha blockers market revenue, by type (2015–2030)
28.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
28.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
28.3 Market Revenue, by End User (2015–2030)
Chapter 29. Saudi Arabia Market Size and Forecast
29.1 Overview
29.2 Market Revenue, by Type (2015–2030)
29.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
29.2.1.1 Alpha blockers market revenue, by type (2015–2030)
29.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
29.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
29.3 Market Revenue, by End User (2015–2030)
Chapter 30. South Africa Market Size and Forecast
30.1 Overview
30.2 Market Revenue, by Type (2015–2030)
30.2.1 Drug Treatment Market Revenue, by Type (2015–2030)
30.2.1.1 Alpha blockers market revenue, by type (2015–2030)
30.2.1.2 5-alpha reductase inhibitors market revenue, by type (2015–2030)
30.2.2 Surgical Treatment Market Revenue, by Type (2015–2030)
30.3 Market Revenue, by End User (2015–2030)
Chapter 31. Competitive Landscape
31.1 List of Market Players and Their Offerings
31.2 Market Share Analysis of Key Players
31.2.1 Global
31.2.2 North America
31.3 Competitive Analysis of Key Players
31.4 Product Comparison of Key Players
31.5 Recent Strategic Developments by Key Players
Chapter 32. Company Profiles
32.1 Pfizer Inc.
32.1.1 Business Overview
32.1.2 Product and Service Offerings
32.1.3 Key Financial Summary
32.2 Company 2
32.2.1 Business Overview
32.2.2 Product and Service Offerings
32.2.3 Key Financial Summary
32.3 Company 3
32.3.1 Business Overview
32.3.2 Product and Service Offerings
32.3.3 Key Financial Summary
32.4 Company 4
32.4.1 Business Overview
32.4.2 Product and Service Offerings
32.4.3 Key Financial Summary
32.5 Company 5
32.5.1 Business Overview
32.5.2 Product and Service Offerings
32.5.3 Key Financial Summary
32.6 Company 6
32.6.1 Business Overview
32.6.2 Product and Service Offerings
32.6.3 Key Financial Summary
32.7 Company 7
32.7.1 Business Overview
32.7.2 Product and Service Offerings
32.7.3 Key Financial Summary
32.8 Company 8
32.8.1 Business Overview
32.8.2 Product and Service Offerings
32.8.3 Key Financial Summary
32.9 Company 9
32.9.1 Business Overview
32.9.2 Product and Service Offerings
32.9.3 Key Financial Summary
32.10 Company 10
32.10.1 Business Overview
32.10.2 Product and Service Offerings
32.10.3 Key Financial Summary
Chapter 33. Appendix
33.1 Abbreviations
33.2 Sources and References
33.3 Related Reports
Get a bespoke market intelligence solution
- Buy report sections that meet your requirements
- Get the report customized as per your needs
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws